Journal of Endocrinological Investigation

, Volume 29, Issue 9, pp 771–775 | Cite as

Long-term effects of elevated gastrin levels on calcitonin secretion

  • M. F. Erdogan
  • A. GursoyEmail author
  • M. Kulaksizoglu
Original Articles


Gastrin and pentagastrin stimulate thyroid C cells and elevate serum calcitonin levels. Gastrin levels may be elevated when histamine-2 receptor blockers (H2RB) and/or proton pump inhibitors (PPI) are used, or in patients with pernicious anemia (PA). This study was designed to investigate the long-term effects of elevated gastrin levels on serum calcitonin levels. We conducted a pentagastrin stimulation test to evaluate C cell reserves in patients who had been using PPI and/or H2RB for an extended period, as well as in patients with PA. We compared the results with a healthy control group of similar age and sex. A total of 40 controls (26 women, 24 men) and 25 patients (15 women, 10 men) using H2RB and/or PPI, and 37 patients (24 women, 13 men) with PA were enrolled. The groups were similar in terms of mean age and sex distribution. Mean fasting gastrin levels, and mean baseline and pentagas-trin-stimulated calcitonin levels were significantly higher in the H2RB+PPI and PA groups than in controls. No significant differences were observed between the H2RB+PPI and PA groups. There was no correlation between gastrin and calcitonin levels. However, mean calcitonin levels were significantly higher in subjects with high baseline gastrin levels than in controls. The prevalence of autoimmune thyroid disease was 32% in the PA group. Patients with PA and thyroiditis had significantly higher baseline gastrin levels than patients with PA only (p<0.01). PA with autoimmune thyroid disease had also significantly higher baseline and penta-gastrin-stimulated calcitonin levels than did PA patients without autoimmune thyroid disease. In conclusion, chronic elevated gastrin levels led to elevated calcitonin levels. Further histopathological studies showing C cell hyperplasia are needed to confirm the mechanism of this relationship.


C cell gastrin calcitonin pentagastrin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaserer K, Scheuba C, Neuhold N, et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. Am J Surg Pathol 1998, 22: 722–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid. Cancer 1996, 77: 750–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Owyang C, Heath H 3rd, Sizemore GW, Go VL. Comparison of the effects of pentagastrin and meal-stimulated gastrin on plasma calcitonin in normal man. Am J Dig Dis 1978, 23: 1084–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Lamers CB, Hackeng WH, Thien T, van Tongeren JH. Serum concentrations of immunoreactive calcitonin in patients with hypergastrinemia. Digestion 1980, 20: 379–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Lazzaroni M, Sangaletti O, Bianchi Porro G. Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients. Hepato-Gastroenterol 1992, 39: 366–70.Google Scholar
  6. 6.
    Lind T, Cederberg C, Forssell H, Olausson M, Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988, 23: 1259–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Fahrenkrug J, Schaffalitzky de Muckadell OB, Rehfeld JF. Serum calcitonin in hypergastrinemia due to achlorhydria. Acta Endocrinol (Copenh) 1977, 86: 140–5.Google Scholar
  8. 8.
    Becker KL, Silva OL, Cyrus J, Snider RH Jr, Moore CF. Hypercalcitonemia in pernicious anemia. Experientia 1980, 36: 1330–1.PubMedCrossRefGoogle Scholar
  9. 9.
    Brandsborg M, Nielsen HE, Brandsborg O, Olsen KJ, Lovgreen NA. The role of serum gastrin in the secretion of calcitonin: studies in patients with pernicious anemia and in healthy subjects. Scand J Gastroenterol 1980, 15: 23–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Rumenapf G, Schwille PO, Wagner W, Tiecks FP, Fries W, Galewski D. Highly selective vagotomy in the rat: effects on bone and mineral metabolism. Scand J Gastroenterol 1994, 29: 232–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Persson P, Grunditz T, Axelson J, Sundler F, Hakanson R. Cholecystokinins but not gastrin-17 release calcitonin from thyroid C-cells in the rat. Regul Pept 1998, 21: 45–56.CrossRefGoogle Scholar
  12. 12.
    Heynen G, Brassine A, Daubresse JC, et al. Lack of clinical and physiological relationship between gastrin and calcitonin in man. Eur J Clin Invest 1981, 11: 331–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Erdogan MF, Gullu S, Baskal N, Uysal AR, Kamel N, Erdogan G. Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma. J Clin Endocrinol Metab 1997, 82: 897–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Babior BM, Bunn HF. Megaloblastic anemias. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL eds. Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill. 2001, 674–80.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2006

Authors and Affiliations

  1. 1.Medical School, Department of Endocrinology and Metabolism, Ibn-i Sina HospitalAnkara UniversitySamanpazariTurkey

Personalised recommendations